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Aim of the work: To identify clinical and serological risk factors that may cause poor maternal
and fetal outcomes in pregnant systemic lupus erythematosus (SLE) patients.
Patients and methods: Forty selected SLE pregnant women (group A) versus 35 non-pregnant
SLE patients (group B). SLE disease activity index (SLEDAI) and ﬂares were evaluated for both
groups. Laboratory investigations included double stranded DNA, anticardiolipin antibodies
(aCL), and complements (C3 & C4). SLE pregnant patients were followed up in the second and
third trimesters by ultrasonography and fetal Doppler were done to assess fetal outcome. Risk fac-
tors for poor maternal and fetal outcome were recorded.
Results: SLEDAI was increased in both groups more in group A. Lupus ﬂares were increased
during pregnancy as it occurred in (62.5%) of group A compared to (37.14%) in group B where
severe ﬂares were more frequent in group A. Gestational hypertension and active SLEDAI were
found statistically signiﬁcant for poor maternal outcome. Fetal outcome included full term
37.5%, prematurity 25%, intra-uterine growth retardation (IUGR) 22.5%, stillbirth 12.5%, abor-
tion 7.5% and congenital heart block (CHB) 2.5%. Factors signiﬁcantly associated with poor fetal
outcome were severe ﬂares and active renal disease where fetal loss signiﬁcantly associated with aCL
antibodies. Full term was more common in patients with no ﬂares.351807; fax: +20 552344552.
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160 H.A. Gaballa et al.Conclusion: These data demonstrate that pregnancy in SLE patients should be considered as a
high-risk pregnancy and conception should be planned during a quiescent period. Close monitoring
for optimal disease control of ﬂares, lupus nephritis, gestational hypertension and aCL antibodies is
recommended.
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Systemic lupus erythematosus (SLE) is a chronic, multisystem,
autoimmune disease that is well recognized to affect the child-
bearing age females, characterized by periods of ﬂuctuating
disease activity [1].
In the past, women with SLE were advised against preg-
nancy. However, with good disease control and rigorous mon-
itoring, there is no reason why the majority of these women
should not have the opportunity to bear children. SLE is an
important risk factor for mother and fetus during pregnancy.
Lupus women are thought to experience disease deterioration
due to pregnancy, but varying incidence and rates have been
reported [2].
Multiple clinical and laboratory factors that have been
identiﬁed in association with the less favorable outcome during
pregnancy include previous nephropathy, maternal hyperten-
sion, ﬂare-up of the disease and positivity for antiphospholipid
antibodies (aPL) [3]. Obstetric complications that may be in-
creased in lupus pregnancies include fetal loss, prematurity,
preeclampsia, intrauterine growth retardation, and neonatal
lupus syndromes [4].
The objective of this study was to identify clinical and sero-
logical risk factors that may cause poor maternal and fetal out-
comes in SLE patients.
2. Patients and methods
2.1. Study subjects and design
Forty SLE pregnant women were selected from inpatient
and outpatient clinics of Rheumatology & Rehabilitation
and Obstetrics & Gynaecology Departments in Zagazig Uni-
versity Hospitals (group A), from March 2008 to October
2010.
Another 35 non-pregnant SLE patients attending Rheu-
matology outpatient clinics were taken as control group
(group B) that were homogenous for age, disease duration,
diagnostic and therapeutic protocol. All patients and controls
met the revised criteria of American College of Rheumatol-
ogy for SLE [5]. Exclusion criteria included therapeutic abor-
tion, patients suffering from diseases other than SLE (e.g.
diabetes or hypertension), preeclampsia, and patients escaped
from follow up.
Patients in group A were ﬁrst booked in the ﬁrst trimester
and followed up in second and third trimester. Maternal infor-
mation included age, past obstetrical history, duration of SLE,
previous and current manifestations of SLE and current med-
ications. Active disease at conception was deﬁned as the use of
>10 mg of prednisone daily, the use of any immunosuppres-
sive agent, or an SLE disease activity index (SLEDAI) score
of >2 [6,7].Non-pregnant SLE patients attending lupus clinic were fol-
lowed up once every 3 months with inactive disease and more
frequent with active disease (increased SLEDAI score of >2).
Both groups were also assessed for disease ﬂare according
to Petri et al. [8] in the ﬁrst visit and once every trimester.
Mild/moderate ﬂare was deﬁned as new or worsened cutane-
ous disease, nasopharyngeal ulcers, pleuritis, pericarditis,
arthritis, fever attributable to SLE, the addition of non-steroi-
dal anti-inﬂammatory drugs or an increase in prednisone up to
a dose of 0.5 mg/kg/d. Severe ﬂare was deﬁned as new or worse
CNS disease; vasculitis; nephritis; myositis; hemolytic anemia;
platelet count less than 60,000/mL; the addition of azathio-
prine, hospitalization for SLE-related manifestations, or an in-
crease in prednisone to >0.5 mg/kg/d.
Gestational hypertension was deﬁned as a systolic blood
pressure P140 mm Hg and diastolic blood pressure P90 mm
Hg on at least two occasions, at least 6 h apart after 20 weeks’
gestation and with normalization of blood pressure postpar-
tum. Antihypertensive drugs were given to patients with blood
pressureP160/100 mm Hg [9,10]. We did not include patients
with previously-induced hypertension as we aimed to study it
as a maternal or fetal risk factor.
Written consents for ethical consideration were taken from
all patients.
2.2. Laboratory procedures
Laboratory data for both groups included ANA, double-
stranded DNA antibody, aCL antibodies, complements (C3
& C4), complete blood count, and urine analysis.
For group A, sequential ultrasound studies and Doppler
analysis of uteroplacental circulation were performed every
2 weeks in the second trimester and weekly thereafter. Anti-
SSA was detected in patients with abnormal ultrasonography
suggesting CHB.
2.3. Therapeutic protocol
It included pre-conceptional treatment which was kept un-
changed as possible. Cyclophosphamide was switched to aza-
thioprine (100 mg/d). Prednisolone dosage was unchanged
until there was a lupus ﬂare, the dose was increased according
to severity of ﬂare. Cases with positive aCL antibody had got
infantile aspirin (75 mg/d) once daily. Low molecular weight
heparin was added to patients with previous thrombosis and
discontinued in the last 10–15 days before delivery.
Statistical methods: Data analysis was performed by using
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). Proportions
were compared using the v2 test and Fisher exact test when
appropriate. Quantitative variables were presented as
mean ± SD and t test for qualitative variables statistical sig-
niﬁcance was set at p< 0.05.
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3.1. Flares in SLE patients
Twenty-ﬁve patients (62.5%) had developed ﬂares in group A,
compared to 13 (37.14%) in group B with signiﬁcant difference
between both of them. Most ﬂares in group A occurred during
the second trimester. No ﬂares were noticed in both groups
more in group B. Mild/moderate ﬂares were more frequent
in both groups than severe ﬂares but the latter more in group
A (Table 2).
3.2. Signiﬁcant predictors of poor maternal outcome
There was signiﬁcant difference and strong evidence of an ef-
fect of gestational hypertension and active SLEDAI at concep-
tion on poor maternal outcome (Table 3).
3.3. Characteristics of fetal outcome
Fig. 3 provides results of fetal outcome where full term and
prematurity had highest incidence (37.5% and 25% respec-
tively) where the lowest was congenital heat block (CHB)
(2.5%). More than one fetal complication may occur in the
same pregnancy. Results of ultrasound studies and Doppler
analysis of uteroplacental circulation of cases from group A
are summarized in Fig. 4.
Doppler analysis was done only when fetal complications
were suspected by ultrasonography. CHB was suggested in
one patient during antenatal visit at 26 weeks’ gestation where
the ultrasonic study detected mild cardiac enlargement and
ventricular bradycardia of 55 bpm. Patient was admitted to
hospital for testing of anti-SSA antibodies which was positiveTable 2 Results of SLE ﬂares in both groups.
Flare Group A n= 40
No ﬂares 15 (37.5%)
Mild/moderate 16 (40%)
Severe 9 (22.5%)
Table 1 First visit characteristics of both SLE groups.
Characteristics Group (A) n = 40
Agea (years) 27.2 ± 6.0
Disease durationa 5.95 ± 3.04
Previous parity 18 (45%)
SLEDAI Active 18 (45%)
SLEDAI inactive 22 (55%)
+ve ANA 40 (100%)
+ve Anti ds-DNA 24 (60%)
aCL (IgG) 11 (27.5%)
aCL (IgM) 4 (10%)
Low C3 8 (20%)
Low C4 5 (12.5%)
aCL (IgG)P 10 [GPL u/m] while aCL (IgM)P 7 [MPL u/ml].
SLE pregnant women with positive aCL (IgM) antibody were also IgG p
a Mean ± SD.and given terbutaline (max. dose 5 mg/6 h) to improve the fetal
heart rate (FHR) and steroids to enhance lung maturity for
48 h with close monitoring and repeated ultrasonography.
One week later ultrasonography showed IUFD.
3.4. Signiﬁcant predictors of poor fetal outcome
Factors signiﬁcantly associated with poor fetal outcome were
severe ﬂares (p= 0.019) and active renal disease (p= 0.05).
Fetal loss was signiﬁcantly increased with the presence of
aCL antibodies especially in the second trimester
(p= 0.016). On the other hand full term was signiﬁcantly asso-
ciated with patients with no ﬂares (p= 0.013) (Table 4).
Initial number of group (A) was 48 but reduced to 40 as 8 of
them were missed from follow up. Table 1 summarizes ﬁrst vis-
it characteristics of both SLE groups, there were no statistical
differences between the 2 groups regarding any variable. IgG-
aCL antibodies in groups A and B were 14 ± 1.7 and
12.1 ± 2.8 respectively, IgM-aCL antibodies in groups A
and B were 8 ± 1.9 and 10.2 ± 2.8 respectively with no statis-
tical difference between both groups. Clinical SLE manifesta-
tions at ﬁrst visit in both groups are presented in Fig. 1,
some patients experienced multiple organ involvement. Lupus
nephritis, arthritis and cutaneous manifestations represented,
in order, the most common clinical ﬁndings. Signiﬁcant differ-
ences between the 2 groups were reported with arthritis, active
renal disease and cutaneous manifestations. It was found that
gestational hypertension had occurred in 6 pregnant SLE
women during pregnancy follow-up. Of the 12 patients with
heparin intake, 9 had previous fetal loss and 3 had previous
deep venous thrombosis (DVT). Fig. 2 shows drugs taken in
the ﬁrst visit steroids, antimalarials, azathioprine, aspirin and
heparin. Dosages were adjusted later according to severity of
ﬂares (data not shown).Group B n= 35 v2 p
21 (60%) 3.79 0.052
10 (28.57%) 1.08 0.29
4 (11.43%) 1.6 0.2
Group (B) n= 35 p
28.9 ± 4.1 0.09
6.6 ± 3.6 0.59
20 (57.14%) 0.29
18 (42.86%) 0.8
20 (57.14%) 0.8
35 (100%) 1.0
20 (57.14%) 0.8
12 (34.28%) 0.52
5 (14.28%) 0.72
12 (34.28%) 0.16
6 (17.14%) 0.57
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Figure 1 Clinical SLE manifestations at the ﬁrst visit.
40
11 12 9
13
35
12
4
11
20
0
7
0
5
10
15
20
25
30
35
40
45
Ste
ro
ids
As
pir
in
He
pa
rin
Az
ath
iop
rin
e
An
tim
ala
ria
ls
Cy
clo
p h
os
ph
am
ide
Drugs
N
um
be
r o
f p
at
ie
nt
s
Group A Group B
Figure 2 Drugs taken at the onset of pregnancy.
Table 3 Factors associated with poor maternal outcome in group A.
Characteristics Flare n= 25 No ﬂare N= 15 p
Age at onset (years)
>35 4 1 0.63
<35 21 14
Disease duration at onset (years)
>5 10 8 0.41
<5 15 7
Hypertension 6 (24%) 0 (0%) 0.04a
Active on SLEDAI at conception 15(60%) 3 (20%) 0.013a
a p value is signiﬁcant.
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Diagnosis of a lupus ﬂare in pregnancy may be difﬁcult. The
effect of pregnancy on SLE activity has received much atten-
tion; however, the exact consequence of pregnancy on the
course of SLE is not conclusively determined [11].
In the present study, lupus ﬂare was increased during preg-
nancy as it occurred in (62.5%) of pregnant SLE patients,
compared to (37.14%) in non-pregnant patients. Some authors
have reported an increased frequency of ﬂares more than
(60%) during pregnancy [12,13]. But others found a rate sim-
ilar to a non-pregnant SLE population [14–16]. Differences inthe deﬁnitions of lupus ﬂare, as well as patient or control
group characteristics as age, race, disease status, and treatment
might contribute to these contradictory results.
Some factors might increase the risk of ﬂares, most studies
agreed that ﬂares occurred more often in SLE patients with ac-
tive disease at conception [1]. A publication from Japan noted
the frequency of SLE ﬂares was (13%) in inactive patients at
conception vs. (75%) in patients with active disease [17].
In this study, mild/moderate ﬂares were more common in
both groups than severe ﬂares. Arthritis and cutaneous
manifestations were the commonest. Most ﬂares in group A
occurred during the second trimester. Some authors had
Figure 4 Shows antenatal follow up by ﬂow velocity waveforms of the umbilical artery in two pregnant patients with SLE, one patient
(A) aged 26 years with disease duration of 1 year had cutaneous manifestations of SLE, negative aCL antibodies and mild ﬂare showed
normal ﬁndings, and other patient (B) aged 38 years with disease duration of 5 years, positive aCL antibodies and severe ﬂare showed
abnormal ﬁndings (absent end diastolic ﬂow and reversed ﬂow in the umbilical artery) suggesting impaired placental circulation, fetal
hypoxia and IUGR.
Table 4 Factors associated with poor fetal outcome.
Full term
n= 15
Fetal
loss n= 9
Poor
outcome
n= 16
Flares
No ﬂare (n= 15) 9a 3 3
Mild/moderate (n= 16) 6 4 6
Severe (n= 9) 0 2 7*
Anti-SSA antibodies (n= 1) 0 0 1
aCL antibodies (n= 11) 1 6* 4
Active renal disease (n= 9) 0 1 8*
Gestational hypertension (n= 6) 1 1 4
* p value is signiﬁcant.
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Figure 3 Results of fetal outcome. Perinatal outcomes included: spontaneous abortion (before 20 weeks’ gestation); stillbirths (dead
fetus and newborn weighing 500 g or more); prematurity (preterm delivery before 37 weeks’ gestation); intrauterine growth restriction
(IUGR) (infants whose weights were below the 10th percentile for their gestational age); congenital heart block.
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partum period [18]. Others reported that the severity of the
ﬂare is mild with arthritis, constitutional and cutaneous
manifestations being common [19]. However, more serious
problems affecting the kidneys and CNS have been reported
in (46% and 14%) of patients, respectively. Therefore, close
monitoring and multidisciplinary care are essential during
the pregnancy [13]. Our SLE patients with renal disease werenot encouraged for pregnancy, especially if they had already
one offspring. This is why the non-pregnant group had fre-
quent renal disease. Cyclophosphamide was stopped in all
pregnant patients causing more frequent renal ﬂares. This issue
was an un-avoidable limiting factor in studying renal disease in
pregnant vs. non-pregnant SLE patients.
In present study, factors signiﬁcantly associated with poor
maternal outcome included gestational hypertension and
active SLEDAI at conception. Some publications [20,21] re-
ported that multiple factors have been identiﬁed in association
with less successful maternal outcome, including lupus activity
during pregnancy, previous nephropathy, maternal hyperten-
sion and positive antiphospholipid antibodies.
Although the outcome of pregnancy in patients with SLE
had improved considerably in the recent years, the frequency
of fetal loss remains higher than that in matched pregnant con-
trols. This is due to greater incidences of prematurity, sponta-
neous abortion and intrauterine death [22].
From review of several studies, the frequency of fetal death
varied from (4% to 43%), which is higher than in the general
population [13,23,24]. In this study, frequency of abortion was
(7.5%) while stillbirth was (12.5%). Another study reported a
4-fold increase in the risk of stillbirth in lupus patients in their
164 H.A. Gaballa et al.study [25]. Several factors may predict fetal death such as lupus
disease activity, active lupus nephritis, and the presence of
antiphospholipid antibodies [26].
In this study, aCL antibodies were present in (27.5%) SLE
pregnant patients. Fetal loss was more likely associated with
aCL antibodies, especially in the second trimester. The associ-
ation between these antibodies and fetal loss had been well
demonstrated in other studies [27,28]. Some authors studied
91 pregnancies, reporting that antiphospholipid antibodies
were more prevalent in patients with recurrent miscarriages
[29]. Mechanisms could include lack of implantation, placental
vasoconstriction and thrombosis leading to either fetal growth
restriction or death [30]. The literature indicated that the pres-
ence of aCL antibodies, especially with high titers, is associated
with an approximately 2-fold increase in fetal loss (as high as
30–83% of pregnancies compared to a 4–43% fetal loss rate
in aCL antibody negative SLE patients) [3].
Lupus was associated with an increased rate of prematurity,
Frequency of preterm deliveries in the general population var-
ies between (4% and 9%) [4]. In this study, it was (25%) in
pregnant SLE patients. While other studies found a range of
(4–62%) [3,23,24]. The discrepancies in the literature might
be due to differences in deﬁnitions of prematurity, the rate
of therapeutic or spontaneous abortions and the fact that pre-
term birth in SLE has multiple causes.
In the present study, IUGR occurs in 22.5% of SLE preg-
nancies. Several studies reported varied ranges from (14.8% to
20.0%) of SLE pregnancies [31–33]. The main factors contrib-
uting to the increased rate of growth restriction are hyperten-
sion, corticosteroids, antiphospholipid antibodies and pre-
eclampsia [3,34]. Low complement levels also seem to correlate
with IUGR [17]. An Egyptian study done by Gheita et al. [35]
had studied the uterine-umbilical artery Doppler velocimetry
and pregnancy outcome in SLE patients. They found IUGR,
IUFD and abortions in (13.89%), (2.78%) and (5.55%) of
SLE cases, which are lower than the current study. This could
be explained that our patients without planned pregnancies in
the current study may have poorer fetal outcome. Pulsed
Doppler is not done routinely; it is done in case of detecting
any fetal abnormality by ultrasound only.
One case of CHB was detected in this study. His mother
was positive anti-SSA antibodies. The exact pathogenesis of fe-
tal CHB is not known. The placental transfer of maternal auto
antibodies in the second trimester could be responsible. Fetal
echocardiography during 16–24 weeks of gestation can help
to detect CHB in utero [36]. In the current study, poor fetal
outcome was increased signiﬁcantly with severe ﬂares and ac-
tive renal disease. This is in agreement with a study reported
where history of nephritis, gestational hypertension and pro-
teinuria >0.5 g/day have been shown to be predictive of ad-
verse fetal outcome in SLE patients [13]. Another recent one
showed that pregnancies in patients with previous nephritis
showed a higher rate of fetal complications than those without
renal involvement [37]. Other researches reported several
strong predictors of poor fetal outcome as maternal hyperten-
sion [6], history of fetal loss, pre-eclampsia and antiphospho-
lipid antibodies [31].
In conclusion, pregnancy in SLE patients should be consid-
ered as a high-risk pregnancy and conception should be
planned, if possible, during a quiescent period. Close monitor-
ing for optimal disease control of ﬂares, lupus nephritis, gesta-
tional hypertension and aCL antibodies is recommended.Multidisciplinary obstetrical care was necessary throughout
the gestation period to increase the chance of a successful
pregnancy.
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